A Randomized, Placebo-Controlled, Phase 2 Study of the Safety and Efficacy of Combination Treatment with Semaglutide, Cilofexor and Firsocostat in Patients With Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis (WAYFIND)

Conference Reports for NATAP

The Liver Meeting
AASLD 2025
Washington, D.C.
November 7-11, 2025


A Randomized, Placebo-Controlled, Phase 2 Study of the Safety and Efficacy of Combination Treatment with Semaglutide, Cilofexor and Firsocostat in Patients With Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis (WAYFIND)

	AASLD 2025 Nov 7-11 Wash DC